A randomized controlled trial to evaluate the efficacy and safety of Clears-belong Plus in participants with long COVID (COVID-19)
- Conditions
- ong COVIDlong COVIDherbal supplementlimebamboo grasscannabisgalangalpepper
- Registration Number
- TCTR20230131004
- Lead Sponsor
- Rangsit University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- All
- Target Recruitment
- 66
1. Thai males and females aged 20 years old or above.
2. Previously had COVID-19 infection as confirmed by ATK or RT-PCR at least 4 weeks before screening.
3. Long COVID diagnosis as confirmed by a physician.
4. Willing to attend all the study procedures.
1. Have or suspected to have penumonitis
2. Have at least one of the following conditions: chronic obstructive pulmonary disease, chronic lung diseases, chronic renal disease, cardiovascular diseases, cerebrovascular diseases, congenital heart diseases, psychotic disorders, hepatitis, cirrhosis, and immunodeficiency disorders
3. Current use of warfarin or benzodiazepines
4. Positive result from tetrahydrocannabinol (THC) urine test at screening
5. Positive result from urine pregnancy test at screening
6. Plan to become pregnant or breastfeeding
7. History of hypersensitivity to any active ingredients of Clears-belong Plus
8. Participating in other studies
9. Any other health conditions that could interfere with participation in this study based on investigator's judgement
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Symptom severity at baseline and end of treatment questionnaire,C-reactive protein level at baseline and end of treatment blood sampling
- Secondary Outcome Measures
Name Time Method Remission of long COVID symptoms at baseline and end of treatment questionnaire,Quality of life at baseline and end of treatment questionnaire,Adverse events after randomization through end of study collection of adverse events by investigators